» Authors » Kenzo Tokunaga

Kenzo Tokunaga

Explore the profile of Kenzo Tokunaga including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 66
Citations 2698
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu C, Jiang F, Li Y, Li Q, Tokunaga K, Yang D, et al.
Microbiol Spectr . 2025 Jan; 13(3):e0274824. PMID: 39868869
ine orporator 5 (INC5, SER5) suppresses viral cell-free infection. However, its antiviral potency under viral cell-cell infection is not examined yet. Here, we established the cell-cell infection systems to assess...
2.
Tada T, Zhang Y, Kong D, Tanaka M, Yao W, Kameoka M, et al.
Cells . 2024 Apr; 13(8. PMID: 38667313
The cellular transmembrane protein MARCH8 impedes the incorporation of various viral envelope glycoproteins, such as the HIV-1 envelope glycoprotein (Env) and vesicular stomatitis virus G-glycoprotein (VSV-G), into virions by downregulating...
3.
Ueda R, Hashimoto R, Fujii Y, Menezes J, Takahashi H, Takeda H, et al.
Membranes (Basel) . 2024 Feb; 14(2). PMID: 38392670
Lysosomal degradation of tyrosinase, a pivotal enzyme in melanin synthesis, negatively impacts melanogenesis in melanocytes. Nevertheless, the precise molecular mechanisms by which lysosomes target tyrosinase have remained elusive. Here, we...
4.
Miyamoto S, Nishiyama T, Ueno A, Park H, Kanno T, Nakamura N, et al.
Proc Natl Acad Sci U S A . 2023 Dec; 120(52):e2314808120. PMID: 38134196
Infectious virus shedding from individuals infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is used to estimate human-to-human transmission risk. Control of SARS-CoV-2 transmission requires identifying the immune correlates that...
5.
Fujita S, Kosugi Y, Kimura I, Tokunaga K, Ito J, Sato K
J Virol . 2023 Sep; 97(10):e0099023. PMID: 37724881
The efficiency of infection receptor use is the first step in determining the species tropism of viruses. After the coronavirus disease 2019 pandemic, a number of SARS-CoV-2-related coronaviruses (SC2r-CoVs) were...
6.
Azarias Da Silva M, Nioche P, Soudaramourty C, Bull-Maurer A, Tiouajni M, Kong D, et al.
Sci Adv . 2023 Aug; 9(31):eadg2122. PMID: 37540749
Since the initial spread of severe acute respiratory syndrome coronavirus 2 infection, several viral variants have emerged and represent a major challenge for immune control, particularly in the context of...
7.
Nakamura A, Kotaki T, Nagai Y, Takazawa S, Tokunaga K, Kameoka M
PLoS One . 2022 Oct; 17(10):e0274829. PMID: 36264936
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a global threat. To forestall the pandemic, developing safe and effective vaccines is...
8.
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, et al.
Med . 2022 Mar; 3(4):249-261.e4. PMID: 35261995
Background: The immune profile against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has dramatically diversified due to a complex combination of exposure to vaccines and infection by various lineages/variants, likely...
9.
Zhang Y, Ozono S, Tada T, Tobiume M, Kameoka M, Kishigami S, et al.
Microbiol Spectr . 2022 Jan; 10(1):e0061821. PMID: 35019698
The host transmembrane protein MARCH8 is a RING finger E3 ubiquitin ligase that downregulates various host transmembrane proteins, such as MHC-II. We have recently reported that MARCH8 expression in virus-producing...
10.
Kimura I, Kosugi Y, Wu J, Zahradnik J, Yamasoba D, Butlertanaka E, et al.
Cell Rep . 2021 Dec; 38(2):110218. PMID: 34968415
SARS-CoV-2 Lambda, a variant of interest, has spread in some South American countries; however, its virological features and evolutionary traits remain unclear. In this study, we use pseudoviruses and reveal...